Clinical Trial AVX - 001

Clinical trial AVX-001 is the first study of PVX108 to be conducted in humans.  The objectives of this trial are:

 

  1. to determine the maximum dose that can be safely administered as a single injection

  2. to assess the safety of repeat, escalating doses, administered once every 2 weeks.


 Recruitment for clinical trial AVX-001 is now complete.

CMAX Clinical Research
Adelaide, South Australia.

 

Ph. 1800 150 433

Centre for Clinical Studies 

Melbourne, Victoria.

 

Ph. 03 8593 9875

Are you interested in participating in future trials?

Please contact info@aravax.com.au